Glenview Trust co Decreases Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Glenview Trust co lessened its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 17.6% during the 4th quarter, HoldingsChannel.com reports. The fund owned 4,051 shares of the medical equipment provider’s stock after selling 868 shares during the quarter. Glenview Trust co’s holdings in Zimmer Biomet were worth $428,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in ZBH. Stonebridge Financial Group LLC purchased a new position in shares of Zimmer Biomet in the fourth quarter valued at approximately $25,000. Dunhill Financial LLC lifted its position in shares of Zimmer Biomet by 1,090.0% in the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 218 shares in the last quarter. Brooklyn Investment Group purchased a new position in shares of Zimmer Biomet in the third quarter valued at approximately $35,000. Kentucky Trust Co purchased a new position in shares of Zimmer Biomet in the fourth quarter valued at approximately $39,000. Finally, OFI Invest Asset Management purchased a new position in shares of Zimmer Biomet in the fourth quarter valued at approximately $40,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Analysts Set New Price Targets

ZBH has been the subject of several recent research reports. Barclays cut their price target on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a report on Monday, February 10th. Royal Bank of Canada cut their price target on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a report on Friday, February 7th. JMP Securities reaffirmed a “market outperform” rating and issued a $140.00 price target on shares of Zimmer Biomet in a report on Friday, February 7th. Truist Financial reaffirmed a “hold” rating and issued a $113.00 price target (down previously from $118.00) on shares of Zimmer Biomet in a report on Monday, February 10th. Finally, Stifel Nicolaus increased their price target on Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a report on Thursday, January 23rd. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $124.15.

Zimmer Biomet Trading Up 1.7 %

Shares of NYSE ZBH opened at $111.85 on Tuesday. Zimmer Biomet Holdings, Inc. has a twelve month low of $97.69 and a twelve month high of $133.90. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. The stock has a fifty day simple moving average of $105.99 and a 200-day simple moving average of $106.90. The stock has a market capitalization of $22.26 billion, a PE ratio of 25.13, a PEG ratio of 1.95 and a beta of 1.04.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period last year, the firm earned $2.20 earnings per share. On average, equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a $0.24 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a yield of 0.86%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 21.57%.

Insider Activity at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the transaction, the senior vice president now directly owns 8,768 shares in the company, valued at approximately $915,379.20. This trade represents a 14.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.95% of the stock is currently owned by company insiders.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.